Mark C. McKenna, Chairman, President & CEO at Prometheus Biosciences, Inc. (RXDX), sold 63,680 shares at $119.87 ($7.7M) on 2023-02-16, disclosed to the SEC on 2023-02-17.
Scheduled sale ($7.7M) by Chairman, President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $119.42 | 25,000 | $3.0M | 38.8% |
| 2 | $119.87 | 25,000 | $3.0M | 39.0% |
| 3 | $125.10 | 13,680 | $1.7M | 22.2% |
| Total | $120.82 avg | 63,680 | $7.7M | 100% |
| Filing → |
| RXDX | SELL | 2023-03-03 | $1.4M | — | Filing → |
| RXDX | SELL | 2023-01-19 | $3.0M | — | Filing → |
| BHC | SELL | 2019-08-21 | $470K | — | Filing → |